ANKTIVA
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- ANKTIVA
- Generic name
- NOGAPENDEKIN ALFA INBAKICEPT-PMLN
- Manufacturer
- Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- eae31db8-3e7a-d9e0-708d-74419d1b50ff
- SPL ID
- 5ed7fe40-a69b-0d42-e063-6394a90a7f64
- Version
- 10
- Effective date
- 2026-10-27
- Source export date
- 2026-11-13
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:31:40
| Harmonized routes |
|---|
| INTRAVESICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 761336 | derived:openfda.application_number |
| application number | BLA761336 | openfda.application_number | |
| brand name | ANKTIVA | openfda.brand_name | |
| generic name | NOGAPENDEKIN ALFA INBAKICEPT-PMLN | openfda.generic_name | |
| manufacturer name | Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc. | openfda.manufacturer_name | |
| ndc | package | 81481-803-01 | openfda.package_ndc |
| ndc | product | 81481-803 | openfda.product_ndc |
| ndc11 | package | 81481080301 | derived:openfda.package_ndc |
| rxcui | 2682691 | openfda.rxcui | |
| rxcui | 2682684 | openfda.rxcui | |
| spl id | 5ed7fe40-a69b-0d42-e063-6394a90a7f64 | id | |
| spl set id | eae31db8-3e7a-d9e0-708d-74419d1b50ff | set_id | |
| unii | 7TK323DLA0 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Delaying cystectomy can lead to the development of metastatic bladder cancer, which can be lethal. ( 5.1 ) 5.1 Risk of Metastatic Bladder Cancer with Delayed Cystectomy Delaying cystectomy in patients with BCG-unresponsive NMIBC could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. The risk of developing muscle invasive or metastatic bladder cancer increases the longer cystectomy is delayed in the presence of persisting BCG-unresponsive NMIBC. Of the 77 evaluable patients with BCG-unresponsive CIS treated with ANKTIVA with TICE BCG in QUILT-3.032, 10% (n = 8) progressed to muscle invasive (T2 or greater) bladder cancer, including 7 during the treatment period. Three patients had progression determined at the time of cystectomy. The median time between determination of persistent or recurrent CIS and progression to muscle-invasive disease was 107 days (range: 0 – 210). If patients with BCG-unresponsive NMIBC have evidence of high-grade disease after a second induction course of ANKTIVA with BCG, reconsider cystectomy.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc. at toll-free phone 877-265-8482 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ANKTIVA in combination with TICE BCG was evaluated in Cohort A of QUILT-3.032, a single-arm, multicenter clinical study in 88 patients with BCG-unresponsive high-grade NMIBC with CIS with or without Ta/T1 papillary disease [see Clinical Studies ( 14 )]. Patients received 400 mcg ANKTIVA with TICE BCG weekly for 6 consecutive weeks during induction and then once a week for every 3 weeks at 4, 7, 10, 13, and 19 months for patients with no or low-grade disease. Patients with persistent CIS or high-grade Ta at 3 months were eligible to receive a second induction. Patients with ongoing complete response at 25 months were eligible to receive additional instillations once a week every 3 weeks at months 25, 31, and 37. The median number of doses of ANKTIVA with BCG administered to patients was 12 (range 2 – 30) doses. The median duration of exposure to ANKTIVA with BCG was 7.1 months (range: 0.26 to 36.3 months). Serious adverse reactions occurred in 16% of patients receiving ANKTIVA with TICE BCG. Serious adverse reactions that occurred in ≥2% of patients who received ANKTIVA with TICE BCG included hematuria (3.4%). A fatal adverse reaction of cardiac arrest occurred in 1 (1.1%) patient receiving ANKTIVA with TICE BCG. Permanent discontinuation of ANKTIVA with TICE BCG due to adverse reactions occurred in 7% of patients. Adverse reactions (>2%) resulting in permanent discontinuation of ANKTIVA with TICE BCG included musculoskeletal pain (2.3%). Dosage interruptions due to adverse reactions occurred in 34% of patients receiving ANKTIVA with TICE BCG. Adverse reactions (≥5%) that resulted in interruption of ANKTIVA with TICE BCG were urinary tract infection (10%), dysuria (8%), hematuria (6%), and bladder irritation (6%). Dosage reductions due to adverse reactions were not permitted for ANKTIVA; however, dose reduction of TICE BCG was allowed for adverse reactions and occurred in 3.4% of patients. Adverse reactions (>1%) that resulted in a dose reduction of TICE BCG included urinary tract infection (2.3%), hematuria (1.1%), urinary frequency (1.1%), and bladder irritation (1.1%). The most common (≥15%) adverse reactions, including laboratory test abnormalities, were increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia. Table 1 summarizes the adverse reactions in Cohort A of QUILT-3.032. Table 1: Adverse Reactions Occurring in ≥15% of Patients in Cohort A in QUILT-3.032 1 Includes other related terms Adverse Reaction ANKTIVA with TICE BCG (n=88) All Grades % Grades 3 or 4 % Dysuria 32 0 Hematuria 1 32 3.4 Urinary Frequency 27 0 Micturition Urgency 1 25 0 Urinary Tract Infection 1 24 2.3 Musculoskeletal Pain 1 17 2.3 Chills 15 0 Pyrexia 15 0 Clinically relevant adverse reactions in <15% of patients who received ANKTIVA with TICE BCG included fatigue (14%), nausea (14%), bladder irritation (11%), diarrhea (9%), and nocturia (7%). Table 2 summarizes the laboratory test abnormalities occurring in ≥15% of patients in QUILT-3.032. Table 2: Select Laboratory Test Abnormalities (≥15%) That Worsened From Baseline in Patients in Cohort A of QUILT-3.032 1 The denominator used to calculate the rates was 88 based on the number of patients with a baseline value and at least one post-treatment value. Laboratory Abnormality ANKTIVA with TICE BCG 1 (n=88) All Grades % Grades 3 or 4 % Increased Creatinine 76 0 Increased Potassium 18 2
adverse reactions table
<table ID="t48773226" border="0" width="100%"> <caption>Table 1: Adverse Reactions Occurring in ≥15% of Patients in Cohort A in QUILT-3.032</caption> <col/> <col/> <col/> <tfoot> <tr> <td colspan="3"> <sup>1</sup>Includes other related terms </td> </tr> </tfoot> <tbody> <tr> <td rowspan="2" align="left" styleCode="Lrule Toprule Rrule Botrule "> <content styleCode="bold">Adverse Reaction</content> </td> <td colspan="2" align="center" styleCode="Lrule Toprule Rrule Botrule "> <content styleCode="bold">ANKTIVA with TICE BCG (n=88) </content> </td> </tr> <tr> <td align="center" styleCode="Lrule Toprule Rrule Botrule "> <content styleCode="bold">All Grades % </content> </td> <td align="center" styleCode="Lrule Toprule Rrule Botrule "> <content styleCode="bold">Grades 3 or 4 % </content> </td> </tr> <tr> <td styleCode="Lrule Toprule Rrule Botrule ">Dysuria</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">32</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">0</td> </tr> <tr> <td styleCode="Lrule Toprule Rrule Botrule ">Hematuria <sup>1</sup> </td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">32</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">3.4</td> </tr> <tr> <td styleCode="Lrule Toprule Rrule Botrule ">Urinary Frequency</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">27</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">0</td> </tr> <tr> <td styleCode="Lrule Toprule Rrule Botrule ">Micturition Urgency <sup>1</sup> </td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">25</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">0</td> </tr> <tr> <td styleCode="Lrule Toprule Rrule Botrule ">Urinary Tract Infection <sup>1</sup> </td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">24</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">2.3</td> </tr> <tr> <td styleCode="Lrule Toprule Rrule Botrule ">Musculoskeletal Pain <sup>1</sup> </td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">17</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">2.3</td> </tr> <tr> <td styleCode="Lrule Toprule Rrule Botrule ">Chills</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">15</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">0</td> </tr> <tr> <td styleCode="Lrule Toprule Rrule Botrule ">Pyrexia</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">15</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">0</td> </tr> </tbody> </table>
adverse reactions table
<table ID="t53884226" border="0" width="100%"> <caption>Table 2: Select Laboratory Test Abnormalities (≥15%) That Worsened From Baseline in Patients in Cohort A of QUILT-3.032</caption> <col/> <col/> <col/> <tfoot> <tr> <td colspan="3"> <sup>1</sup>The denominator used to calculate the rates was 88 based on the number of patients with a baseline value and at least one post-treatment value. </td> </tr> </tfoot> <tbody> <tr> <td rowspan="2" align="left" styleCode="Lrule Toprule Rrule Botrule " valign="top"> <content styleCode="bold">Laboratory Abnormality</content> </td> <td colspan="2" align="center" styleCode="Lrule Toprule Rrule Botrule "> <content styleCode="bold">ANKTIVA with TICE BCG <sup>1</sup> (n=88) </content> </td> </tr> <tr> <td align="center" styleCode="Lrule Toprule Rrule Botrule "> <content styleCode="bold">All Grades % </content> </td> <td align="center" styleCode="Lrule Toprule Rrule Botrule "> <content styleCode="bold">Grades 3 or 4 % </content> </td> </tr> <tr> <td styleCode="Lrule Toprule Rrule Botrule ">Increased Creatinine</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">76</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">0</td> </tr> <tr> <td styleCode="Lrule Toprule Rrule Botrule ">Increased Potassium</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">18</td> <td align="center" styleCode="Lrule Toprule Rrule Botrule ">2</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.